John and Scott are back!  Join us for a quick catch up and hear about what's coming as The Biotech Project kicks up into high gear.  Sorry about the echo on John's mic LOL!

Join us as we chat with Mary Jean Fanelli, a seasoned medical affairs professional who's held roles on both the global and U.S. stage. Her fascinating journey from pediatrician to biotech world is rife with insightful experiences and rich knowledge about the industry worth sharing. In the ever-evolving landscape of biotech, strategic decisions can make or break a company. Mary Jean opens about the critical choice of focusing on prevalent diseases versus rare diseases. She gets real about her hands-on experience working on treatments for cystic fibrosis and talks about how game-changing advancements in the field have transformed fatal conditions into manageable chronic diseases through gene therapies. Looking towards the future, we navigate the shifting dynamics of medical affairs and its interactions. Our conversation takes a deep dive into how commercial and medical affairs might collaborate moving forward and how the roles within might evolve. From discussing the valuable skills needed to transition between roles to how these roles can synergize for rare diseases, Mary Jean provides an eye-opening perspective. So, get set for an engaging listen that charts a captivating medical journey and a peek into the future of medical affairs.

Join us on the Biotech Project podcast as we sit down with Jeff Galvin, the CEO and Founder of American Gene Technologies. Jeff is a visionary in the field of gene therapy and has been at the forefront of developing innovative treatments. In this episode, we delve into the inner workings of American Gene Technologies, the company's current projects and pipeline, including their goal of curing HIV.  We also explore the challenges and opportunities facing the biotech industry. Additionally, Jeff will share his insights on the future of gene therapy and the impact it will have on healthcare. Tune in to gain an in-depth understanding of the future of gene therapy from one of its leading figures.